

1 **Estimated pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the**
2 **COVID-19 pandemic**

3 Karl W. Boehme, PhD^{1,2,3#}, Joshua L. Kennedy, MD^{4,5,6,#}, Jessica Snowden, MD⁴, Shana M.
4 Owens, PhD¹, Marianne Kouassi, BS¹, Ryan L. Mann, BS¹, Amairani Paredes, BS¹, Claire Putt,
5 BA⁴, Laura James, MD⁴, Jing Jin, MPH⁷, Ruofei Du, PhD⁷, Catherine Kirkpatrick, BS⁶, Zeel
6 Modi, BA⁵, Katherine Caid, BS⁵, Namvar Zohoori, MD, MPH, PhD^{7,8}, Atul Kothari, MD^{5,8,9},
7 Bobby L. Boyanton, Jr., MD¹⁰, and J. Craig Forrest, PhD^{1,2,3}

8
9 ¹ Department of Microbiology & Immunology, College of Medicine, University of Arkansas for
10 Medical Sciences, Little Rock, AR

11 ² Center for Microbial Pathogenesis and Host Inflammatory Responses, University of Arkansas
12 for Medical Sciences, Little Rock, AR

13 ³ Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little
14 Rock, AR

15 ⁴ Department of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences,
16 Little Rock, AR

17 ⁵ Department of Internal Medicine, College of Medicine, University of Arkansas for Medical
18 Sciences, Little Rock, AR

19 ⁶ Arkansas Children's Research Institute, Little Rock, AR.

20 ⁷ Department of Biostatistics, College of Public Health, University of Arkansas for Medical
21 Sciences, Little Rock, AR

22 ⁸ Arkansas Department of Health, Little Rock, AR.

23 ⁹ Department of Bioinformatics, College of Medicine, University of Arkansas for Medical
24 Sciences, Little Rock, AR

25 ¹⁰ Departments of Pathology, Arkansas Children's Hospital and University of Arkansas for
26 Medical Sciences, Little Rock, AR

27
28 #These authors contributed equally to the work.

29
30 ‡ Correspondence to:

31 Karl W. Boehme

32 Mailing address: 4301 W. Markham Dr. #511, Little Rock, AR 72205

33 Phone: (501) 686-5189

34 Email: kwboehme@uams.edu

35
36 J. Craig Forrest

37 Mailing address: 4301 W. Markham Dr. #511, Little Rock, AR 72205

38 Phone: (501)

39 Email: jcforrest@uams.edu

40
41 Joshua L. Kennedy

42 Mailing address: 13 Children's Way, Slot 512-13, Little Rock, AR 72205

43 Phone: (501) 364-1060

44 Email: jlkenedy@uams.edu

45
46 Running Title: Pediatric SARS-CoV-2 seroprevalence in Arkansas

47 Keywords: COVID-19, SARS-CoV2, serology, antibody, child, epidemiology

48 **ABSTRACT**

49 **Importance:** As vaccines for children under the age of 12 are not yet approved, determining the
50 SARS-CoV-2 infection rate in children is important for decisions about protective measures to
51 be taken during the 2021–2022 school year.

52
53 **Objective:** To estimate the prevalence of SARS-CoV-2 antibodies in residual serum samples
54 from pediatric patients in the state of Arkansas over the first year of the COVID-19 pandemic as
55 an indicator of SARS-CoV-2 infection rates in children.

56
57 **Design:** The study is a survey of SARS-CoV-2 seropositivity in children in Arkansas over the
58 first year of the COVID-19 pandemic. From April 2020 through April 2021, remnant serum
59 samples were collected across five time periods (waves): April 2–May 6, June 6–August 10,
60 September 8–October 17, November 7–December 17, 2020 and April 5–April 28, 2021.

61
62 **Setting:** The multi-site survey collected remnant serum samples from four clinics across the
63 state of Arkansas: Arkansas Children’s Hospital (ACH, Little Rock, AR), Arkansas Children’s
64 Northwest (Springdale, AR), and UAMS Family Medical Centers (Ft. Smith, AR and Pine Bluff,
65 AR)

66
67 **Participants:** The study population consisted of 2400 convenience serum samples from
68 children ages 1–18 who visited hospitals or regional clinics in Arkansas for non-COVID19-
69 related reasons.

70
71 **Exposures:** Infection with SARS-CoV-2.

72

73 **Main outcomes and measures:** The presence of IgM and/or IgG antibodies to the SARS-CoV-
74 2 Spike and Nucleoprotein were determined using a two-step enzyme-linked immunosorbent
75 assay. Seroprevalence was estimated by demographic group, including age (1-4, 5-9, 10-14,
76 and 15-18 years), sex, race/ethnicity (white, black, Hispanic), metropolitan status, SARS-CoV-2
77 PCR testing, and co-morbidities (respiratory virus infection within 6 months, asthma,
78 hypertension, obesity, diabetes, autoimmune disease). Association with SARS-CoV-2 antibody
79 reactivity was determined by demographic group.

80

81 **Results:** The overall SARS-CoV-2 seroprevalence rose from 7.9% in Wave 1 (95%CI, 4.9-
82 10.9%) to 25.8% in Wave 5 (95% CI, 22.2-29.3%), as did the age- and sex-standardized
83 seroprevalence rate which ranged from 8.6% in Wave 1 (95%CI, 5.1-11.1%) to 24.2% in Wave
84 5 (95% CI, 20.1-28.2%). Hispanic children had a significantly higher risk of testing positive for
85 SARS-CoV-2 antibodies than non-Hispanic white children in Wave 3 (RR 2.82, 95% CI, 1.81-
86 4.38), Wave 4 (RR 1.76, 95% CI, 1.03-3.00), and Wave 5 (RR 2.37, 95% CI, 1.69-3.33)
87 Similarly, black children also showed a significantly higher risk of testing positive for SARS-CoV-
88 2 antibodies than white children in Wave 3 (RR 1.71, 95% CI, 1.03-2.84) and Wave 5 (RR 1.59,
89 95% CI, 1.08-2.34).

90

91 **Conclusions and relevance:** The percentage of Arkansas children with SARS-CoV-2-specific
92 antibodies increased from April 2020 to April 2021. These data indicate that many more children
93 have been infected with SARS-CoV-2 than indicated by diagnostic testing. With the emergence
94 of SARS-CoV-2 variants, recognition of long-term effects of SARS-CoV-2 even after mild or
95 asymptomatic infections, and the lack of an authorized pediatric SARS-CoV-2 vaccine, these
96 results highlight the importance of including children in SARS-CoV-2 public health, clinical care,
97 and research strategies. These findings are important for state and local officials as they

- 98 consider measures to limit SARS-CoV-2 spread in schools and daycares for the 2021–2022
- 99 school year.

100 INTRODUCTION

101 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in late 2019
102 and spread globally to cause the coronavirus disease of 2019 (COVID-19) pandemic.^{1,2} SARS-
103 CoV-2 has infected nearly 200 million and killed more than 4 million people worldwide, causing
104 massive disruptions to daily life and untold economic losses.³ SARS-CoV-2 was first detected in
105 the United States in early 2020 and has caused over 600,000 deaths.⁴⁻⁶ Children were thought
106 to be important for driving SARS-CoV-2 transmission.^{7,8} In March 2020, schools nationwide
107 closed for in-person instruction and classes moved online to curtail SARS-CoV-2 spread.^{7,8}
108 However, pediatric infection rates, and thereby the potential level of immunity in children, is not
109 known.^{9,10} Because approval of SARS-CoV-2 vaccines for those 12 years and under is not
110 expected until late 2021, knowing infection rates in children is important information for school
111 officials as they consider risks and protection measures for the 2021–2022 school year.

112 Children typically experience less severe COVID-19 and may be more likely to have
113 asymptomatic infections, allowing them to unknowingly spread SARS-CoV-2.¹¹ With
114 asymptomatic infections estimated as high as 50%, estimating true infection rates remains
115 challenging.^{12,13} Although nucleic acid testing can identify active SARS-CoV-2 cases, most
116 infections clear within two weeks and leave asymptomatic cases undocumented.¹²⁻¹⁴ Antibodies
117 generated against prior infections can last for months to years.^{10,15} The presence of SARS-CoV-
118 2 antibodies in the blood can indicate that a person was infected at some point in the pandemic.
119 Serological studies can capture asymptomatic and symptomatic cases, and more accurately
120 estimate of how many people have been infected with SARS-CoV-2.^{10,15} Here, we present the
121 results of a seroprevalence study of children ages 1–18 years of age who visited hospitals or
122 regional clinics for non-COVID19-related reasons in the state of Arkansas over the first year of
123 the COVID-19 pandemic.

124

125

126 **METHODS**

127 **Human specimens.** All human specimens were obtained with oversight from the UAMS
128 Institutional Review Board (IRB), and waiver of consent and HIPAA applied. Remnants of serum
129 samples collected for routine, non-COVID-19-related clinical laboratory tests were obtained from
130 Arkansas Children's Hospital (ACH, Little Rock, AR), Arkansas Children's Northwest
131 (Springdale, AR), and UAMS Family Medical Centers (Ft. Smith, AR and Pine Bluff, AR).
132 Samples were de-identified prior to testing. Inclusion criteria were ages 1–18 years and
133 Arkansas resident. Samples were excluded with the following diagnosis codes:
134 immunodeficiency (primary immune deficiency (D80–D89)), transplant recipient (codes
135 beginning with Z94), and cancer (C00–D49). Samples from patients receiving chemotherapy
136 (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months)
137 were excluded. Samples were selected by pathologists at each clinic after they were considered
138 remnant. Clinical and demographic variables were stored in a secure REDCap database^{16,17}
139 and included age, sex, race, ethnicity, zip code, and county of residence. Metropolitan status
140 was determined by cross-referencing zip codes with the Federal Office of Rural Health Policy
141 (FORHP) data files identifying non-metropolitan counties and rural census tracts.

142 **Protein production and purification.** HEK 293T cells were cultured in Dulbecco's
143 minimum essential media (DMEM; Gibco) supplemented with 10% heat-inactivated calf serum
144 (CS, VWR), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin/100 µg/mL streptomycin
145 (Invitrogen). Briefly, 15 cm dishes seeded with 9×10^6 cells on the preceding day were
146 transfected with 20 µg of pCAGGS-SARS-CoV-2 Wuhan-Hu-1 RBD with C-terminal 6-His tag
147 (BEI Resources), pCAGGS SARS-CoV-2 Wuhan-Hu-1 ectodomain Spike glycoprotein gene
148 with C-terminal 6-His tag, or pCMV3 2019-nCoV nucleoprotein with C-terminal 6-His tag (Sino
149 Biological) using polyethylamine (PEI) at a 1:3 ratio. DNA:PEI mixtures were incubated at RT for
150 10 mins and added to cells with the media volume reduced to 5 mL/dish. After 4–6 hours, the
151 media volume was raised to 25 mL. SARS-CoV-2 RBD and Spike ectodomain proteins were

152 purified as described.¹⁸ Nucleoprotein (N) was isolated as described above under denaturing
153 conditions.¹⁹ Protein concentration was measured by DC Protein Assay (BioRad). Purified
154 proteins were confirmed by Coomassie and western blot using antigen-specific antibodies and
155 stored at -80°C .

156 **ELISAs.** Serum was inactivated at 56°C for 1 h and initially screened by ELISA specific
157 for the receptor-binding domain (RBD) of the SARS-CoV-2 S protein.²⁰⁻²⁶ Commercial anti-RBD
158 (Sino Biologicals; 1:2500 dilution) and SARS-CoV-2-RT-PCR-positive patient sera (1:50
159 dilution) served as positive controls. Purified human IgG (Sigma; 1:2500 dilution) and pre-
160 COVID-19 patient sera (1:50 dilution) served as negative controls. Serum IgM and IgG were
161 detected using horse-radish peroxidase-conjugated anti-human IgM+IgG (Jackson
162 ImmunoResearch; diluted 1:5000 in PBS-T + 1% milk) and SureBlue TMB 1-Component
163 Peroxidase Substrate (SeraCare; 75 μL). After 5 min, the reaction was terminated using TMB
164 Stop Solution (SeraCare; 75 μL). The OD_{450} was measured using a FluoStar Omega plate
165 reader (BMG Labtech). The final OD_{450} was calculated by subtracting the mean OD_{450} of blank
166 wells from the mean OD_{450} of duplicate samples. The statistical cutoff for RBD binding was
167 defined as the mean OD_{450} + 3 standard deviations of pre-COVID-19 sera.²⁶

168 Confirmation RBD-positive specimens was performed using a Four-Antigen Confirmation
169 Test (FACT) ELISA. An additional 5% of negative sera were randomly selected and tested in
170 parallel. Plates were coated with 2 $\mu\text{g}/\text{mL}$ RBD, spike, nucleoprotein, or bovine serum albumin
171 (BSA; Sigma Aldrich) and FACT ELISA was performed as above. Confirmed positive samples
172 were defined by (i) a mean signal for any viral antigen over 0.6 OD_{450} , (ii) BSA-subtracted viral
173 antigen value $>0.3 \text{OD}_{450}$, (iii) and at least two positive antigens (RBD+/Spike+, RBD+/N+,
174 Spike+/N+, or RBD+/Spike+/N+). The sensitivity and specificity of the assay were 94.6% and
175 100%, respectively, based on 37 pre-COVID-19 and 19 RT-PCR-confirmed SARS-CoV-2-
176 positive sera.

177 **Statistical analyses.** The descriptive analysis was conducted for the study population
178 demographics by wave. SARS-CoV-2 antibody positivity rates were reported with 95%
179 confidence intervals (CI) using exact binomial distributions. The 2019 U.S. Census Bureau
180 Arkansas state population estimates (age \leq 18) were used to calculate the standardized positivity
181 rates.²⁷ The age- and sex-standardized positivity rates were reported for each wave. Univariable
182 and multivariable analyses were performed to examine the relationship between variables and
183 the SARS-CoV-2 antibody positivity rate for each wave. Relative risk was estimated by modified
184 Poisson regressions with robust error variance as the measure to characterize association
185 effects.²⁸ For multivariable analyses, factors being considered were age group, sex, and
186 race/ethnicity. The statistical significance level was set at 0.05. We conducted all analyses using
187 SAS version 9.4 (SAS Institute).

188

189 **RESULTS**

190 **Enrollment and demographic representation.** We collected 2400 total remnant
191 pediatric serum samples across five collection periods: Wave 1, April 2–May 6, 2020 (n=316);
192 Wave 2, June 6–August 10, 2020, (n=300); Wave 3, September 8–October 17, 2020, (n=594);
193 Wave 4, November 7–December 17, 2020, (n=600); and Wave 5, April 5–April 28, 2021,
194 (n=590) (Figure 1). Table 1 shows the demographic characteristics for the study. The 1–4 years
195 age group had the fewest samples (n=328, 13.7%) while the 10–14 years group had the most
196 samples (n=795, 33.2%). Females represented 54.8% (n=1311), whereas males represented
197 45.2% (n=1082) of total samples analyzed. The racial/ethnic distribution of the study population
198 was 55.8% non-Hispanic white (n=1289), 22.5% non-Hispanic black (n=520), and 15.2%
199 Hispanic (n=351). A total of 151 specimens (6.5%) were collected from patients that did not
200 identify as white, black, or Hispanic. Most samples were collected from children living in urban
201 (n=1564, 75.3%) compared to rural areas (n=513, 24.7%). Obesity was the most common co-

202 morbidity reported (n=337, 14.1%), followed by asthma (n=239, 10.0%), diabetes mellitus
203 (n=113, 4.7%), and hypertension (n=111, 4.6%) (Supplemental table 1).

204 **Estimates of seroprevalence.** Table 2 shows the SARS-CoV-2 seroprevalence rates
205 by age, sex, and race/ethnicity, and the age- and sex-standardized estimates. The antibody
206 positivity rate for Wave 1 was 7.9% (95% CI, 4.9%-10.9%), which increased in Wave 2 to 9.7%
207 (95% CI, 6.3%-13.0%) and Wave 3 to 16.2% (95% CI, 13.2%-19.1%), followed by a slight
208 decrease to 13.2% (95% CI, 10.5%-15.9%) in Wave 4. The seroprevalence rate was the highest
209 in Wave 5 at 25.8% (95% CI, 22.2%-29.3%). The overall trend was statistically significant
210 ($p < 0.0001$ using the Cochran-Armitage trend test). When standardized to match Arkansas
211 population demographics,²⁷ seroprevalence rates followed a similar trend to the non-adjusted
212 rates, increasing over Waves 1, 2, and 3, with a decrease in Wave 4 and a peak of 24.2% (95%
213 CI, 22.2%-29.3%) in Wave 5. The 1–4 year-old age group had the highest seroprevalence rates
214 in Wave 1 (10.7%), Wave 2 (15.2%), and Wave 3 (19.8%), but the lowest in Wave 4 (7.2%) and
215 Wave 5 (16.0%). The 15-18 year-old group had the highest percentage of reactive specimens in
216 Wave 4 (14.8%) and 10-14 year-olds were the highest in Wave 5 (30.9%). No statistically-
217 significant difference was observed between males and females.

218 Hispanics had the highest seroprevalence rate in each wave, reaching a maximum of
219 43.7% in Wave 5. White persons had a higher seroprevalence rate in Waves 1 and 2, but the
220 lowest in Waves 3, 4, and 5. Concomitantly, the antibody reactivity rate in black persons was
221 lower compared to white persons in Waves 1 and 2, but higher in Waves 3, 4, and 5. The
222 highest seroprevalence rates for white (17.9%) and black (28.2%) children was observed in
223 Wave 5. Notably, the peak seroprevalence for Hispanic children was 5.5-fold higher compared
224 to white children and 1.6-fold higher than black children.

225 There was no significant marginal association between age, sex, or metropolitan status
226 and the likelihood of testing positive for SARS-CoV-2 antibodies (Supplemental table 2).
227 However, Hispanic and black children were more likely to test positive for antibodies than white

228 children during multiple waves after adjusting for age and sex. Hispanic children showed a
229 higher relative risk of testing positive compared to white children in Wave 3 (RR 2.82 95% CI,
230 1.81-4.38), Wave 4 (RR 1.76 95% CI, 1.03-3.00), and Wave 5 (RR 2.37 95% CI 1.69-3.33).
231 Blacks also showed a higher risk of having antibodies compared to white children in Wave 3
232 (RR 1.71 95% CI, 1.03-2.84) and Wave 5 (RR 1.59 95% CI, 1.08-2.34). The risk of testing
233 positive for antibodies was higher for children of other races/ethnicities in Wave 3 (RR 2.59 95%
234 CI, 1.36-4.92) and Wave 5 (RR 2.14 95% CI, 1.35-3.40).

235 Children with asthma (unadjusted RR 4.83 95% CI, 1.96-11.87; $P=0.003$) or diabetes
236 (unadjusted RR 4.17 95% CI, 1.49-11.67; $P=0.007$) had higher risk of having antibodies of
237 SARS-CoV-2 than children who did not have asthma or diabetes in Wave 1 (Supplemental table
238 3). However, this difference was not observed in the remaining waves. PCR testing was
239 performed for 714 of 2400 total specimens, with 38 positive PCR tests reported (Supplemental
240 table 4). A positive RT-PCR test was significantly associated with antibody positivity in Waves 2
241 through 5 (Supplemental table 5).

242

243 **DISCUSSION**

244 Our results demonstrate that by the end of April 2021, approximately 25% of children in
245 Arkansas had SARS-CoV-2-specific antibodies. This percentage is much higher than the total
246 number of confirmed cases, which on April 28, 2021 was 11% for the total population of
247 Arkansas (335,288 positive cases according the Arkansas Department of Health, population of
248 3,011,524 according to 2019 census data). This finding indicates that those children had been
249 infected with SARS-CoV-2 and are likely to have at least some natural immunity. Conversely,
250 our findings suggest that most children in Arkansas have not been infected with SARS-CoV-2
251 and remain susceptible to infection. Although COVID-19 has been less severe in children than
252 adults early in the pandemic, emergence of the SARS-CoV-2 delta variant in May 2021 has
253 driven up infection and hospitalization rates, including among those under 18 years of age.^{11,29,30}

254 Developing multisystem inflammatory syndrome in children (MIS-C), a severe inflammatory
255 disorder that results from a current or recent SARS-CoV-2 infection, is also a risk for those
256 under 18 years.³¹⁻³³ Increased SARS-CoV-2 transmission rates combined with a highly
257 susceptible pediatric population raises the possibility that SARS-CoV-2 could spread rapidly in
258 schools and daycares during the upcoming school year. More children infected with SARS-CoV-
259 2 could lead to an increase in the number of severe COVID-19 and MIS-C cases, and a rise in
260 pediatric deaths.

261 The first SARS-CoV-2 infections in Arkansas were reported in March 2020 (Figure 1).³⁴
262 Arkansas schools suspended in-person learning on March 15, 2020 and many activities where
263 children congregate during the summer were closed. We found that the seroprevalence rate in
264 children increased modestly between spring and summer, suggesting that these protective
265 measures effectively limited SARS-CoV-2 spread among children in Arkansas. The larger
266 increase in seroprevalence for September/October (Wave 3), corresponded with the start of the
267 2020-2021 school year. However, masks and social distancing measures were in place, and
268 many Arkansas students began the school year as remote learners. These actions likely
269 reduced SARS-CoV-2 spread in schools, as reported outbreaks were relatively rare. Despite a
270 dramatic increase in SARS-CoV-2 cases in Arkansas during November and December, the
271 seroprevalence rate in children dropped during Wave 4.³⁵ The decrease suggests that
272 preventative measures in schools were effective at limiting SARS-CoV-2 spread among children
273 during this time. However, seroprevalence increased sharply in Wave 5 to approximately 25%.
274 Waves 4 and 5 were approximately three months apart and included the winter holidays, when
275 children were outside the controlled school setting,
276 and the corresponding nationwide surge in COVID-19 cases. Our data confirm that the surge
277 also impacted the pediatric population, correlating with a large increase in the number of SARS-
278 CoV-2-exposed children.

279 It is well appreciated that underrepresented racial and ethnic groups are
280 disproportionately affected by the COVID-19 pandemic.³⁶ We found that Hispanic children were
281 more likely to have SARS-CoV-2 antibodies compared to white children in all waves. Similarly,
282 black children were more likely to have antibodies than white children in Wave 3 and Wave 5.
283 The increase in SARS-CoV-2 antibodies in Hispanic and black children corresponded to an
284 increase in antibody level in Hispanic and black adults during the same timeframe.(REF-
285 Kennedy preprint) Higher antibody prevalence in Hispanic and black children may reflect
286 multiple socioeconomic factors, including income inequality, economic stability, work
287 circumstances, and housing.³⁷ Hispanic and black parents may be less likely to hold jobs that
288 allow them to work remotely, which increases their potential exposure to SARS-CoV-2 in the
289 workplace and limits their ability to utilize remote learning or in home childcare to decrease their
290 children's SARS-CoV-2 exposure.^{38,39} Residing with parents with a higher risk of workplace
291 SARS-CoV-2 exposure combined with increased school/daycare attendance could drive
292 infection rates in minority children. Our results underscore that the pandemic exacerbated
293 existing racial and ethnic disparities.

294 Our data also highlight the importance of vaccinating children against SARS-CoV-2.
295 General vaccinations in Arkansas began in January 2021 for those over 18 years and, and were
296 expanded to 16 years and older on March 30, 2021.⁴⁰ The CDC's Advisory Committee on
297 Immunization Practices recommended the Pfizer-BioNTech vaccine for 12-15 year-olds on May
298 10, 2021.⁴⁰ Wave 5 samples were collected in April 2021, after the expansion of vaccinations to
299 those 16 years and up but prior to inclusion of 12-15 year-olds. Only 8 of 145 total 16-18 year-
300 olds in reported being vaccinated during Wave 5 and no subjects reported full vaccination at
301 least two weeks prior to sample collection. Thus, our data reflect the pediatric seroprevalence
302 rate in Arkansas prior to widespread vaccination efforts in children and adolescents. As
303 authorization to vaccinate children younger than 12 years will not occur until late 2021, our
304 findings indicate that most children in Arkansas remain susceptible to SARS-CoV-2 infection

305 entering the 2021–2022 school year. Importantly, we found that the seroprevalence rate in
306 younger children was lower than for older children and adolescents, which strongly emphasizes
307 the ongoing risk of infection for a vulnerable part of the population that cannot yet be
308 vaccinated. This is a critical consideration for policy makers as more infectious variants emerge
309 that exhibit increased infection and likelihood of causing severe disease in younger portions of
310 the population.

311 **Limitations**

312 Remnant serum samples may not provide an accurate representation of the Arkansas
313 population. The strengths and limitations of convenience samples are described elsewhere.⁴¹
314 As our study samples were collected from health clinics, our sampling method may favor
315 subjects who were more ill or more willing to seek health care. It is possible that our
316 seroprevalence rates are overestimated due to potential cross reactivity between SARS-CoV-2
317 antigens and seasonal coronaviruses.⁴² Some uninfected individuals, particularly children and
318 adolescents, have antibodies that react with the SARS-CoV-2 Spike protein.⁴² Further, we
319 measured a combination of IgM and IgG antibody isotypes, as opposed to testing solely for
320 IgG.⁴³ Although studies indicate that IgG and IgM responses to SARS-CoV-2 can develop
321 simultaneously, some individuals develop detectable IgM and IgG antibodies at different
322 times.^{44,45} Consequently, we may identify individuals that developed IgM and/or IgG, whereas
323 other assays may only identify specimens with IgG. Moreover, IgM can be more non-specific
324 than IgG.⁴⁶ Together, these limitations may cause an overestimation of antibody reactivity.
325 However, inclusion of multiple SARS-CoV-2 antigens and the BSA control limit the number of
326 non-specific reactions detected in our assay.

327

328 **CONCLUSIONS**

329 Analysis of remnant samples collected from children and adolescents in Arkansas
330 demonstrate a steady increase in SARS-CoV-2 infection during the first 8 months of the

331 pandemic, followed by a more rapid increase to 25% by the end of April 2021. This finding is
332 notable, as it is more than twice the number of confirmed SARS-CoV-2 diagnoses in the state
333 on the final collection date. No obvious comorbidities were identified for seropositivity in
334 children. Racial and ethnic disparities exist, with Hispanic and black children being at increased
335 risk for SARS-CoV-2 infection compared to white children. We conclude that SARS-CoV-2
336 infections in children are more common than previously recognized. With the emergence of
337 SARS-CoV-2 variants, recognition of long-term effects of SARS-CoV-2 even after mild or
338 asymptomatic infections, and the lack of an authorized pediatric SARS-CoV-2 vaccine, these
339 results highlight the importance of including children in SARS-CoV-2 public health, clinical care,
340 and research strategies. Until vaccines are approved for those under 12 years, it is important
341 that protective measures are enacted, particularly in settings where children are grouped
342 together, to limit the risk of infection, super-spreader events, severe disease, long-term
343 sequelae, and death. This is especially true in states like Arkansas with low vaccination rates,
344 which is currently experiencing a new surge in infections and hospitalizations in younger age-
345 groups caused by more infectious SARS-CoV-2 variants.

346

347 **ACKNOWLEDGMENTS**

348 This research was supported by funds from the state of Arkansas through the
349 Coronavirus Aid, Relief, and Economic Security (CARES) Act, the UAMS Time-Sensitive
350 COVID-10 Research Award Program, the UAMS Translational Research Institute
351 (UL1TR000039, TL1TR003109, and UL1TR003107), and the Center for Microbial Pathogenesis
352 and Host Inflammatory Response (P20 GM103625).

353

354 **FIGURE LEGENDS**

355 **Figure 1** Timeline of Arkansas COVID-19 milestones and sample collection waves. The
356 schematic shows the timeline for relevant study-related events. The sample collection periods
357 are indicated by blue boxes. The seroprevalence rate for each wave is indicated as the percent
358 (95% CI).

359 **Author Contributions:** Drs. Boehme, Forrest, and Kennedy had full access to all of the data in
360 the study and take responsibility for the integrity of the data and the accuracy of the analysis.

361

362 *Study concept and design:* Boehme, Forrest, Kennedy, Snowden

363

364 *Acquisition, analysis or interpretation of the data:* Boehme, Boyanton, Caid, Forrest, Owens,

365 Kennedy, Kirkpatrick, Kothari, Kouassi, Mann, Modi, Paredes, Putt, Zohoori

366

367 *Draft of the manuscript:* Boehme, Forrest, Kennedy, Owens

368

369 *Critical revision of the manuscript for important intellectual content:* Boehme, Forrest, James,

370 Kennedy, Owens, Snowden

371

372 *Statistical analysis:* Jin, Du

373

374 *Obtained funding:* Boehme, Forrest, James, Kennedy

375

376 *Administrative, technical, or material support:* Boehme, Boyanton, Forrest, James, Kennedy,

377 Snowden

378 REFERENCES

- 379 1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in wuhan,
380 china: The mystery and the miracle. *J Med Virol.* 2020;92(4):401-402.
- 381 2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in
382 china, 2019. *N Engl J Med.* 2020;382(8):727-733.
- 383 3. World health organization. *WHO Coronavirus Dashboard* <https://covid19.who.int/>.
- 384 4. Team CC-R, Jorden MA, Rudman SL, et al. Evidence for limited early spread of covid-19
385 within the united states, january-february 2020. *MMWR Morb Mortal Wkly Rep.*
386 2020;69(22):680-684.
- 387 5. United states centers for disease control and prevention. *COVID Data Tracker*
388 <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>.
- 389 6. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the
390 united states. *N Engl J Med.* 2020;382(10):929-936.
- 391 7. Jean-Baptiste CO, Herring RP, Beeson WL, Dos Santos H, Banta JE. Stressful life
392 events and social capital during the early phase of covid-19 in the u.S. *Soc Sci Humanit*
393 *Open.* 2020;2(1):100057.
- 394 8. Bayham J, Fenichel EP. Impact of school closures for covid-19 on the us health-care
395 workforce and net mortality: A modelling study. *Lancet Public Health.* 2020;5(5):e271-
396 e278.
- 397 9. Hobbs CV, Drobeniuc J, Kittle T, et al. Estimated sars-cov-2 seroprevalence among
398 persons aged <18 years - mississippi, may-september 2020. *MMWR Morb Mortal Wkly*
399 *Rep.* 2021;70(9):312-315.
- 400 10. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated sars-cov-2 seroprevalence in the us
401 as of september 2020. *JAMA Intern Med.* 2021;181(4):450-460.
- 402 11. Dong Y, Mo X, Hu Y, et al. Epidemiology of covid-19 among children in china. *Pediatrics.*
403 2020;145(6).
- 404 12. Oran DP, Topol EJ. Prevalence of asymptomatic sars-cov-2 infection. *Ann Intern Med.*
405 2021;174(2):286-287.
- 406 13. Oran DP, Topol EJ. The proportion of sars-cov-2 infections that are asymptomatic : A
407 systematic review. *Ann Intern Med.* 2021;174(5):655-662.
- 408 14. United states centers for disease control and prevention. *CDC Diagnostic Tests for*
409 *COVID-19* <https://www.cdc.gov/coronavirus/2019-ncov/lab/testing.html>.
- 410 15. Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to sars-cov-2 in 10 sites
411 in the united states, march 23-may 12, 2020. *JAMA Intern Med.* 2020.
- 412 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
413 data capture (redcap)--a metadata-driven methodology and workflow process for
414 providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-
415 381.
- 416 17. Harris PA, Taylor R, Minor BL, et al. The redcap consortium: Building an international
417 community of software platform partners. *J Biomed Inform.* 2019;95:103208.
- 418 18. Stadlbauer D, Amanat F, Chromikova V, et al. Sars-cov-2 seroconversion in humans: A
419 detailed protocol for a serological assay, antigen production, and test setup. *Curr Protoc*
420 *Microbiol.* 2020;57(1):e100.
- 421 19. Mark J, Li X, Cyr T, Fournier S, Jaentschke B, Hefford MA. Sars coronavirus: Unusual
422 lability of the nucleocapsid protein. *Biochem Biophys Res Commun.* 2008;377(2):429-
423 433.
- 424 20. Leclercq I, Batejat C, Burguiere AM, Manuguerra JC. Heat inactivation of the middle east
425 respiratory syndrome coronavirus. *Influenza Other Respir Viruses.* 2014;8(5):585-586.
- 426 21. Yunoki M, Urayama T, Yamamoto I, Abe S, Ikuta K. Heat sensitivity of a sars-associated
427 coronavirus introduced into plasma products. *Vox Sang.* 2004;87(4):302-303.

- 428 22. Rabenau HF, Cinatl J, Morgenstern B, Bauer G, Preiser W, Doerr HW. Stability and
429 inactivation of sars coronavirus. *Med Microbiol Immunol*. 2005;194(1-2):1-6.
- 430 23. Kariwa H, Fujii N, Takashima I. Inactivation of sars coronavirus by means of povidone-
431 iodine, physical conditions and chemical reagents. *Dermatology*. 2006;212 Suppl 1:119-
432 123.
- 433 24. Duan SM, Zhao XS, Wen RF, et al. Stability of sars coronavirus in human specimens
434 and environment and its sensitivity to heating and uv irradiation. *Biomed Environ Sci*.
435 2003;16(3):246-255.
- 436 25. Chang L, Yan Y, Wang L. Coronavirus disease 2019: Coronaviruses and blood safety.
437 *Transfus Med Rev*. 2020;34(2):75-80.
- 438 26. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect sars-cov-2
439 seroconversion in humans. *Nat Med*. 2020;26(7):1033-1036.
- 440 27. United states census bureau. *Quickfacts: Arkansas 2021*;
441 <https://www.census.gov/quickfacts/AR>. Accessed May 14, 2021.
- 442 28. Zou G. A modified poisson regression approach to prospective studies with binary data.
443 *Am J Epidemiol*. 2004;159(7):702-706.
- 444 29. Havers FP, Whitaker M, Self JL, et al. Hospitalization of adolescents aged 12-17 years
445 with laboratory-confirmed covid-19 - covid-net, 14 states, march 1, 2020-april 24, 2021.
446 *MMWR Morb Mortal Wkly Rep*. 2021;70(23):851-857.
- 447 30. Dougherty K, Mannell M, Naqvi O, Matson D, Stone J. Sars-cov-2 b.1.617.2 (delta)
448 variant covid-19 outbreak associated with a gymnastics facility - oklahoma, april-may
449 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(28):1004-1007.
- 450 31. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in
451 children in new york state. *N Engl J Med*. 2020;383(4):347-358.
- 452 32. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in u.S.
453 Children and adolescents. *N Engl J Med*. 2020;383(4):334-346.
- 454 33. Ouldali N, Yang DD, Madhi F, et al. Factors associated with severe sars-cov-2 infection.
455 *Pediatrics*. 2021;147(3).
- 456 34. James A, Eagle L, Phillips C, et al. High covid-19 attack rate among attendees at events
457 at a church - arkansas, march 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(20):632-
458 635.
- 459 35. Arkansas department of health. *COVID-19 Tracker*
460 <https://experience.arcgis.com/experience/633006d0782b4544bd5113a314f6268a/>.
461 Accessed July 20, 2021.
- 462 36. Khunti K, Platt L, Routen A, Abbasi K. Covid-19 and ethnic minorities: An urgent agenda
463 for overdue action. *BMJ*. 2020;369:m2503.
- 464 37. United states bureau of labor statistics. *Labor force characteristics by race and ethnicity,*
465 *2019* <https://www.bls.gov/opub/reports/race-and-ethnicity/2019/home.htm>. Accessed
466 July 22, 2021.
- 467 38. Yancy CW. Covid-19 and african americans. *JAMA*. 2020;323(19):1891-1892.
- 468 39. Ambrose AJH. Inequities during covid-19. *Pediatrics*. 2020;146(2).
- 469 40. Arkansas pharmacists association. *COVID Vaccine 2021*; [https://www.arrx.org/covid-](https://www.arrx.org/covid-vaccine)
470 [vaccine](https://www.arrx.org/covid-vaccine). Accessed May 30, 2021.
- 471 41. Shook-Sa BE, Boyce RM, Aiello AE. Estimation without representation: Early severe
472 acute respiratory syndrome coronavirus 2 seroprevalence studies and the path forward.
473 *J Infect Dis*. 2020;222(7):1086-1089.
- 474 42. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to
475 sars-cov-2 in humans. *Science*. 2020;370(6522):1339-1343.
- 476 43. Oved K, Olmer L, Shemer-Avni Y, et al. Multi-center nationwide comparison of seven
477 serology assays reveals a sars-cov-2 non-responding seronegative subpopulation.
478 *EClinicalMedicine*. 2020;29:100651.

- 479 44. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to sars-cov-2 in patients with
480 covid-19. *Nat Med.* 2020;26(6):845-848.
- 481 45. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of
482 asymptomatic sars-cov-2 infections. *Nat Med.* 2020;26(8):1200-1204.
- 483 46. Shah J, Liu S, Potula HH, et al. Igg and igm antibody formation to spike and
484 nucleocapsid proteins in covid-19 characterized by multiplex immunoblot assays. *BMC*
485 *Infect Dis.* 2021;21(1):325.
- 486

487

488
489

Table 1. Demographics of sampled populations in Arkansas during 5 periods of SARS-CoV-2 antibody testing from April 2, 2020 to April 28, 2021.

Number (%) ^a						
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)	Overall (N = 2400)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021	April 2, 2020 – April 28, 2021
Age category						
1-4 years	56 (17.7)	33 (11)	81 (13.6)	83 (13.9)	75 (12.8)	328 (13.7)
5-9 years	61 (19.3)	75 (25)	112 (18.9)	116 (19.5)	142 (24.2)	506 (21.1)
10-14 years	90 (28.5)	98 (32.7)	205 (34.5)	214 (36.0)	188 (32)	795 (33.2)
15-18 years	109 (34.5)	94 (31.3)	196 (33)	182 (30.6)	183 (31.1)	764 (31.9)
Sex						
Female	161 (50.9)	155 (51.7)	324 (54.5)	338 (56.8)	333 (56.5)	1311 (54.8)
Male	155 (49.1)	145 (48.3)	270 (45.5)	257 (43.2)	255 (43.2)	1082 (45.2)
Race/Ethnicity						
White	178 (56.5)	154 (52.2)	327 (57.2)	312 (54.5)	318 (57.2)	1289 (55.8)
Black	91 (28.9)	53 (18.0)	117 (20.5)	150 (26.2)	109 (19.6)	520 (22.5)
Hispanic	28 (8.9)	64 (21.7)	95 (16.6)	77 (13.4)	87 (15.7)	351 (15.2)
Other	18 (5.7)	24 (8.1)	33 (5.8)	34 (5.9)	42 (7.6)	151 (6.5)
Metropolitan status ^b						
Urban	Not Reported	251 (83.7)	458 (77.1)	424 (71.3)	431 (73.3)	1564 (75.3)
Rural	Not Reported	49 (16.3)	136 (22.9)	171 (28.7)	157 (26.7)	513 (24.7)

^aPercentages calculated from non-missing values for all periods. Missing values in Wave 1 included race/ethnicity (n=1) and metropolitan status (n=316). Missing values in Wave 2 included race/ethnicity (n=5). Missing values in Wave 3 included race/ethnicity (n=22). Missing values in Wave 4 included age category (n=5), sex (n=5), race/ethnicity (n=27), and metropolitan status (n=5). Missing values in Wave 5 included age category (n=4), sex (n=2), race/ethnicity (n=34), and metropolitan status (n=2).

490
491
492
493
494

495
496

Table 2. Age-specific, sex-specific, race/ethnicity-specific seroprevalence estimates in Arkansas during 5 periods of SARS-CoV-2 antibody testing from April 2, 2020 to April 28, 2021.

Characteristic	Persons reactive, % (95% CI) (No.)				
	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021
Age category					
1-4 years	10.7 (2.4-19.1) (6)	15.2 (2.2-28.1) (5)	19.8 (10.9-28.6) (16)	7.2 (1.54-12.9) (6)	16.0 (7.5-24.5) (12)
5-9 years	4.9 (0.0-10.5) (3)	8.0 (1.7, 14.3) (6)	18.8 (11.4-26.1) (21)	12.9 (6.7-19.1) (15)	19.0 (12.5,-25.5) (27)
10-14 years	8.9 (2.9-14.9) (8)	11.2 (4.9-17.6) (11)	14.2 (9.3-19.0) (29)	14.0 (9.3-18.7) (30)	30.9 (24.2-37.5) (58)
15-18 years	7.3 (1.4-12.3) (8)	7.4 (2.0-12.9) (7)	15.3 (10.2-20.4) (30)	14.8 (9.6-20.0) (27)	29.5 (22.8-36.2) (54)
Sex					
Female	8.7 (4.3-13.1) (14)	9.0 (4.5-13.6) (14)	17.3 (13.1-21.4) (56)	13.6 (9.9-17.3) (46)	27.0 (22.2-31.8) (90)
Male	7.1 (3.0-11.2) (11)	10.3 (5.3-15.4) (15)	14.8 (10.6-19.1) (40)	12.5 (8.4-16.5) (32)	23.9 (18.7-29.2) (61)
Race/Ethnicity					
White	9.0 (4.7-13.2) (16)	9.7 (5.0-14.5) (15)	10.7 (7.3-14.1) (35)	11.5 (8.0-15.1) (36)	17.9 (13.7-22.2) (57)
Black	5.5 (0.7-10.3) (5)	3.8 (0.0-9.1) (2)	17.1 (10.2-24.0) (20)	15.3 (9.5-21.2) (23)	28.4 (19.8-37.0) (31)
Hispanic	10.7 (0.0-22.9) (3)	14.1 (5.3-22.8) (9)	29.5 (20.1-38.8) (28)	20.8 (11.5-30.0) (16)	43.7 (33.0-54.3) (38)
Other	5.6 (0.0 -7.3) (1)	12.5 (0.0-26.8) (3)	27.3 (11.2-43.4) (9)	2.9 (0.0-8.9) (1)	35.7 (20.6-50.8) (15)
Total	7.9 (4.9-10.9) (25)	9.7 (6.3-13.0) (29)	16.2 (13.2-19.1) (96)	13.2 (10.5-15.9) (79)	25.8 (22.2-29.3) (152)
Age- and sex-Standardized seroprevalence rate ^a , % (95% CI)	8.6 (5.1-12.1)	9.8 (6.1-13.6)	16.9 (13.3-20.6)	12.5 (9.6-15.5)	24.2 (20.1-28.2)

497
498

^aStandardized positivity rates were calculated based on the 2019 U.S. Census Bureau Arkansas state population estimates (age ≤ 18).²⁷

499 **Table 3. Age- and sex-adjusted association with SARS-CoV-2 antibody positivity by time period.**

Adjusted RR (95% CI)					
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 592)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021
Age category					
1-4 years	1.66 (0.55-5.02)	1.89 (0.67-5.35)	1.41 (0.82-2.43)	0.62 (0.26-1.45)	0.50 (0.28-0.90)
5-9 years	0.65 (0.18-2.41)	0.97 (0.34-2.74)	1.46 (0.88-2.41)	0.95 (0.52-1.75)	0.72 (0.47-1.09)
10-14 years	1.23 (0.46-3.29)	1.36 (0.54-3.43)	0.95 (0.59-1.53)	1.04 (0.64-1.68)	0.90 (0.66-1.24)
15-18 years	Ref	Ref	Ref	Ref	Ref
Sex					
Female	1.37 (0.61-3.06)	0.88 (0.44-1.75)	1.04 (0.71-1.52)	1.12 (0.73-1.73)	1.06 (0.80-1.40)
Male	Ref	Ref	Ref	Ref	Ref
Race/Ethnicity					
Black	0.59 (0.23-1.54)	0.41 (0.09-1.83)	1.71 (1.03-2.84)	1.31 (0.80-2.14)	1.59 (1.08-2.34)
Hispanic	1.21 (0.37-3.93)	1.53 (0.70-3.37)	2.82 (1.81-4.38)	1.76 (1.03-3.00)	2.37 (1.69-3.33)
Other	0.54 (0.07-4.36)	1.25 (0.41-3.81)	2.59 (1.36-4.92)	0.25 (0.04-1.80)	2.14 (1.35-3.40)
White	Ref	Ref	Ref ^a	Ref	Ref ^a

^aIndicates P value < 0.0001 for race/ethnicity in the statistical model.

500
501

502 **Supplemental table 1. Co-morbidities of sampled populations in Arkansas during 5 periods of SARS-CoV-2 antibody testing**
 503 **from April 2, 2020 to April 29, 2021.**

Characteristic	Number (%) ^a					
	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)	Overall (N = 2400)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021	April 2, 2020 – April 28, 2021
Respiratory viral panel within 6 months	Not Reported	34 (11.3)	35 (5.9)	25 (4.2)	Not reported	94 (6.3)
Asthma	12 (3.8)	31 (10.3)	68 (11.5)	62 (10.4)	66 (11.2)	239 (10.0)
Hypertension	16 (5.1)	16 (5.3)	25 (4.2)	34 (5.7)	20 (3.4)	111 (4.6)
Obesity	14 (4.4)	46 (15.3)	83 (14.0)	109 (18.3)	85 (14.4)	337 (14.1)
Diabetes	10 (3.2)	15 (5.0)	30 (5.1)	27 (4.5)	31 (5.3)	113 (4.7)
Autoimmune disease	Not Reported	7 (2.3)	14 (2.4)	19 (3.2)	23 (3.9)	63 (3.0)

504 ^a Percentages calculated from non-missing values for all periods. Missing values in Wave 1 included respiratory virus panel performed within 6 months (n = 316) and autoimmune
 505 disease (n = 316), Missing values in Wave 4 included respiratory virus panel performed within 6 months (n = 5), asthma (n = 5), hypertension (n = 5), obesity (n = 5), diabetes (n = 5),
 506 and autoimmune disease (n = 5). Missing values in Wave 5 included Respiratory viral panel within 6 months (n = 590).
 507
 508
 509

510
511
512

Supplemental table 2. Marginal association between SARS-CoV-2 antibody positivity and demographic characteristics by time period.

Characteristic ^a	Wave 1 (n = 316)			Wave 2 (n = 300)			Wave 3 (n = 594)			Wave 4 (n = 600)			Wave 5 (n = 590)		
	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95%CI)	P ^b	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95% CI)	P ^b
Total	25 (7.9)			29 (9.7)			96 (16.2)			79 (13.2)			152 (25.8)		
Age category			0.690			0.539			0.560			0.410			0.001
1-4	6 (10.7)	1.46 (0.53-4.00)		5 (15.2)	2.03 (0.69-5.97)		16 (19.8)	1.29 (0.75-2.23)		6 (7.2)	0.49 (0.21-1.14)		12 (16.0)	0.54 (0.31-0.95)	
5-9	3 (4.9)	0.67 (0.18-2.43)		6 (8.0)	1.07 (0.38-3.06)		21 (18.8)	1.23 (0.74-2.03)		15 (12.9)	0.87 (0.48-1.57)		27 (19.0)	0.64 (0.43-0.97)	
10-14	8 (8.9)	1.21 (0.47-3.10)		11 (11.2)	1.51 (0.61-3.72)		29 (14.2)	0.92 (0.58-1.48)		30 (14.0)	0.95 (0.58-1.53)		58 (30.9)	1.05 (0.77-1.43)	
15-18	8 (7.3)	Ref		7 (7.5)	Ref		30 (15.3)	Ref		27 (14.8)	Ref		54 (29.5)	Ref	
Sex			0.600			0.701			0.417			0.679			0.332
Female	14 (8.7)	1.23 (0.57, 2.62)		14 (9.0)	0.87 (0.44, 1.74)		56 (17.3)	1.17 (0.80, 1.69)		46 (13.6)	1.09 (0.72, 1.67)		90 (27.0)	1.13 (0.85, 1.50)	
Male	11 (7.1)	Ref		15 (10.3)	Ref		40 (14.8)	Ref		32 (12.5)	Ref		61 (23.9)	Ref	
Race/ethnicity			0.706			0.352			<0.0001			0.060			0.001
Black	5 (5.5)	0.61 (0.23-1.62)		2 (3.8)	0.39 (0.09-1.64)		20 (17.1)	1.60 (0.96-2.65)		23 (15.3)	1.33 (0.82-2.16)		31 (28.4)	1.59 (1.09-2.32)	
Hispanic	3 (10.7)	1.19 (0.37-3.83)		9 (14.1)	1.44 (0.67-3.13)		28 (29.5)	2.75 (1.77-4.28)		16 (20.8)	1.80 (1.06-3.07)		38 (43.7)	2.44 (1.74-3.41)	
Others	1 (5.6)	0.62 (0.09-4.39)		3 (12.5)	1.28 (0.40-4.10)		9 (27.3)	2.55 (1.34-4.83)		1 (2.9)	0.25 (0.04-1.80)		15 (35.7)	1.99 (1.25-3.18)	
White	16 (9.0)	Ref		15 (9.7)	Ref		35 (10.7)	Ref		36 (11.5)	Ref		57 (17.9)	Ref	
Metropolitan status			NA			0.091			0.602			0.876			0.001
Urban	NA	NA		28 (11.2)	5.47 (0.76-39.24)		76 (16.6)	1.13 (0.72-1.78)		55 (13.0)	0.96 (0.61-1.52)		101 (23.4)	0.74 (0.55-0.98)	
Rural				1 (2.0)	Ref		20 (14.7)	Ref		23 (13.5)	Ref		50 (31.9)	Ref	

^a Missing values from Table 1 were not included in the analysis.

^b P-value indicates whether the positivity differs between the category of a respective variable.

513
514
515
516

517
518

Supplemental table 3. Marginal association between SARS-CoV-2 antibody positivity and comorbidities by time period.

Characteristic ^a	Wave 1 (n = 316)			Wave 2 (n = 300)			Wave 3 (n = 594)			Wave 4 (n = 600)			Wave 5 (n = 590)		
	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95%CI)	P ^b	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95% CI)	P ^b
Total	25 (7.9)			29 (9.7)			96 (16.2)			79 (13.2)			152 (25.8)		
Respiratory virus panel within 6 months						0.090			0.517						
Yes	NA	NA	NA	6 (17.7)	2.04 (0.89-4.65)		7 (20.0)	1.26 (0.63-2.50)		0	NA	NA	NA	NA	NA
No				23 (8.7)	Ref		89 (15.9)	Ref		78 (13.7)					
Asthma			0.003			0.192			0.099			0.231			0.71
Yes	4 (33.3)	4.83 (1.96-11.87)		5 (16.1)	1.81 (0.74-4.40)		6 (8.8)	0.52 (0.23-1.13)		5 (8.1)	0.59 (0.25-1.40)		16 (24.2)	0.93 (0.60-1.47)	
No	21 (6.9)	Ref		24 (8.9)	Ref		90 (17.1)	Ref		73 (13.7)	Ref		136 (26.0)	Ref	
Hypertension			NA			0.643			0.258			0.775			0.31
Yes	0	NA		1 (6.3)	0.63 (0.09-4.37)		6 (24.0)	1.52 (0.74-3.13)		5 (14.7)	1.13 (0.49-2.61)		7 (35.0)	1.38 (0.74-2.54)	
No	25 (8.3)			28 (9.9)	Ref		90 (15.8)	Ref		73 (13.0)	Ref		145 (25.4)	Ref	
Obesity			0.914			0.763			0.607			0.589			0.96
Yes	1 (7.1)	0.90 (0.13-6.18)		5 (10.9)	1.15 (0.46-2.86)		15 (18.1)	1.14 (0.69-1.88)		16 (14.7)	1.15 (0.69-1.91)		20 (23.5)	0.90 (0.60-1.36)	
No	24 (8.0)	Ref		24 (9.5)	Ref		81 (15.9)	Ref		62 (12.8)	Ref		132 (26.1)	Ref	
Diabetes			0.007			NA			0.938			0.391			0.96
Yes	3 (30.0)	4.17 (1.49-11.67)		0	NA		5 (16.7)	1.03 (0.45-2.35)		2 (7.4)	0.55 (0.14-2.14)		12 (38.7)	1.55 (0.97-2.46)	
No	22 (7.2)	Ref		29 (10.2)			91 (16.1)	Ref		76 (13.4)	Ref		140 (25.0)	Ref	
Autoimmune disease			NA			0.670			0.849			0.739			0.96
Yes	NA	NA		1 (14.3)	1.49 (0.24-9.49)		2 (14.3)	0.88 (0.24-3.22)		2 (10.5)	0.80 (0.21-3.01)		7 (30.4)	1.19 (0.63-2.24)	
No				28 (9.6)	Ref		94 (16.2)	Ref		76 (13.2)	Ref		145 (25.6)	Ref	

^aMissing values from Table 1 were not included in the analysis.

^bP-value indicates whether the positivity differs between the category of a respective variable.

517
518
519
520
521
522

523 **Supplemental table 4. PCR test history and results from sampled populations in Arkansas during 5 periods of SARS-CoV-2**
 524 **antibody testing from April 2, 2020 to April 28, 2021.**

Number (%) ^a						
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)	Overall (N = 2400)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021	April 2, 2020 – April 28, 2021
SARS-CoV-2 RT-PCR test administered						
Yes	64 (20.3)	82 (27.3)	160 (26.9)	173 (29.1)	235 (39.8)	714 (29.8)
No	252 (79.7)	218 (72.7)	434 (73.1)	422 (70.9)	355 (60.2)	1681 (70.2)
SARS-CoV-2 RT-PCR test result						
Positive	0 (0.0)	1 (1.2)	6 (3.8)	11 (6.4)	20 (8.6)	38 (5.3)
Negative	64 (100)	81 (98.8)	154 (96.2)	162 (93.6)	214 (91.5)	675 (94.7)

^a Percentages calculated from non-missing values for all periods. Missing values in Wave 1 included SARS-CoV-2 RT-PCR test result (n = 252). Missing values in Wave 2 included SARS-CoV-2 RT-PCR test result (n = 218). Missing values in Wave 3 included SARS-CoV-2 RT-PCR test result (n = 434). Missing values in Wave 4 included SARS-CoV-2 RT-PCR test administered (n = 5) and SARS-CoV-2 RT-PCR test result (n = 427). Missing values in Wave 5 included SARS-CoV-2 PCR test result (n = 356)

525
 526
 527
 528

 529
 530

531
532
533

Supplemental table 5. Marginal association between SARS-CoV-2 antibody positivity and SARS-CoV-2 PCR testing by time period.

Characteristic ^a	Wave 1 (n = 316)			Wave 2 (n = 300)			Wave 3 (n = 594)			Wave 4 (n = 600)			Wave 5 (n = 590)		
	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95%CI)	P ^b	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95% CI)	P ^b
Total	25 (7.9)			29 (9.7)			96 (16.2)			79 (13.2)			152 (25.8)		
COVID-19 test administered			0.585			0.178			0.589			0.655			0.485
Yes	4 (6.3)	0.75 (0.27-2.11)		11 (13.4)	1.62 (0.80-3.29)		28 (17.5)	1.12 (0.75-1.67)		21 (12.1)	0.90 (0.56-1.44)		57 (24.3)	0.91 (0.68-1.20)	
No	21 (8.3)	Ref		18 (8.3)	Ref		68 (15.7)	Ref		57 (13.5)	Ref		95 (26.8)	Ref	
COVID-19 PCR result						<0.0001			<0.0001			<0.0001			<0.0001
Positive	0	NA	NA	1 (100)	8.10 (4.53-14.47)		4 (66.7)	4.28 (2.18-8.40)		8 (72.7)	9.06 (4.80-17.10)		17 (85.0)	4.55 (3.25-6.35)	
Negative	4 (6.3)			10 (12.4)	Ref		24 (15.6)	Ref		13 (8.0)	Ref		40 (18.7)	Ref	

^a Missing values from Table 1 were not included in the analysis.

^b P-value indicates whether the positivity differs between the category of a respective variable.

534
535
536
537

